The Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in AprilPivot represents a differentiated solution for insulin-dependent adults still on multiple daily

<ul><li><p><i><strong>The Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in April</strong></i></p></li><li><p><i><strong>Pivot represents a differentiated solution for insulin-dependent adults still on multiple daily injections, representing a multi-billion-dollar market</strong></i></p></li><li><p><i><strong>Commercial expansion activities are expected to begin in Q4 2026</strong></i></p></li></ul> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 24, 2026 / </strong>Modular Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MODD">MODD</a>), a leader in innovative, patient-centric insulin delivery technology, today announced that the Pivot<sup>&#8482;</sup> tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company's transition to a commercial-stage medical device company.</p><p>As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required - all while maintaining clinical accuracy and connectivity.</p><p>"Reaching commercial availability is a transformational milestone that marks Modular Medical's transition from a development-stage company to a revenue-generating commercial business," said Jeb Besser, Chief Executive Officer of Modular Medical. "As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved 'almost-pumper' population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders."</p><p>Pivot is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group, which the Company calls the "almost-pumpers," represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.</p><p>Full commercial launch is expected to roll out in phases, initially targeting select high-volume endocrinology practices and expanding across multiple metropolitan markets by late 2026.</p><p>For more information on the Pivot system, visit the dedicated site: PivotPump.com and the YouTube Pivot Insulin Delivery System channel searchable @ModularMedical.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to convert patients to use its Pivot pump product, whether the Company will have initial users by June 30, 2026, successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, and general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.</p><p><strong>About Modular Medical</strong></p><p>Modular Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MODD">MODD</a>) is a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."</p><p>Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at <a rel="nofollow" href="https://protect.checkpoint.com/v2/r01/___https:/pr.report/NyQvWeDS___.YXAzOm1vZHVsYXItbWVkaWNhbDpjOm86MmQwYWQ5YTU1YjMyNTE4ZmIzOWJiMTNlYTlmOTkwYzU6NzozNGI4OjI2MTFkNzY0OTRlY2Y0ODgyN2FkZDQ1MzhlZGU1YTcxYjMzZGEwNzVlMDkxZjYxZTExNzFiNjY0N2M2ZmQyMzE6cDpUOk4">https://modular-medical.com</a>.</p><p>Pivot is a trademark of Modular Medical in the United States. All other trademarks mentioned herein are the property of their respective owners.</p><p><strong>Company Contact:</strong><br/>Jeb Besser<br/>Chief Executive Officer<br/>Modular Medical, Inc.<br/>+1 (617) 399-1741<br/><a rel="nofollow" href="mailto:IR@modular-medical.com">IR@modular-medical.com</a></p><p><strong>Investor Relations Contact:</strong><br/>Valter Pinto, Managing Director<br/>KCSA Strategic Communications<br/><a rel="nofollow" href="mailto:ModularMedical@KSCA.com">ModularMedical@KSCA.com</a></p><p><strong>SOURCE: </strong>Modular Medical, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-announces-commercial-availability-of-pivot-tubeless-i-1180351'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1180351" width="0" height="0"/>

MODD

Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump Ahead of Commercial Expansion

Modular Medical launches Pivot tubeless insulin pump; US commercial rollout begins

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>The Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in AprilPivot represents a differentiated solution for insulin-dependent adults still on multiple daily</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Pivot tubeless insulin patch pump is now commercially available in the U.S., signaling Modular Medical&#039;s shift to a revenue-generating stage after FDA clearance in April. First shipments have begun, with a phased national rollout planned for late 2026, targeting the large &#039;almost-pumper&#039; segment, a multi-billion-dollar opportunity that could sustain MODD&#039;s near-term growth trajectory.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Pivot tubeless insulin patch pump is now commercially available in the U.S.</li><li>Pivot targets adults on injections, addressing a multi-billion diabetes technology market.</li><li>Full commercial launch planned in phases by late 2026.</li><li>MODD transitions from development to a revenue-generating commercial business.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Modular Medical, Inc. (MODD)</strong>: Pivot launch marks a transition to revenue generation; potential near-term growth driver.</li><li><strong>Pivot Pump (N/A)</strong>: Product enabling MODD&#039;s revenue ramp; directly tied to near-term commercial milestones.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments / Industry News. The press release signals a strategic milestone and revenue inflection for MODD, with potential to re-rate shares if early adoption proves durable and expands into late-2026 markets.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Pivot commercial availability provides near-term revenue visibility for MODD.</li><li>Late-2026 phased rollout could unlock material upside if adoption accelerates.</li><li>Addressable &#039;almost-pumpers&#039; represent a multi-billion-dollar opportunity.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>FDA 510(k) clearance achieved in April 2026.</li><li>Pivot is the second fully electronic tubeless pump in the U.S.</li><li>Pivot features a 3 mL reservoir and removable two-part design.</li><li>First shipments began; full launch planned for late 2026.</li><li>Approximately 70% of insulin-dependent adults are on multiple daily injections.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>bullish: MODD should benefit from early Pivot revenue visibility and a late-2026 expansion, with potential multiple expansion if adoption accelerates.</p>
  </section>
</section>


<ul><li><p><i><strong>The Pivot tubeless insulin patch pump is now commercially available in the U.S. following FDA 510(k) clearance in April</strong></i></p></li><li><p><i><strong>Pivot represents a differentiated solution for insulin-dependent adults still on multiple daily injections, representing a multi-billion-dollar market</strong></i></p></li><li><p><i><strong>Commercial expansion activities are expected to begin in Q4 2026</strong></i></p></li></ul> <p><strong id="dateline">SAN DIEGO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 24, 2026 / </strong>Modular Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MODD">MODD</a>), a leader in innovative, patient-centric insulin delivery technology, today announced that the Pivot<sup>&#8482;</sup> tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company's transition to a commercial-stage medical device company.</p><p>As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required - all while maintaining clinical accuracy and connectivity.</p><p>"Reaching commercial availability is a transformational milestone that marks Modular Medical's transition from a development-stage company to a revenue-generating commercial business," said Jeb Besser, Chief Executive Officer of Modular Medical. "As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved 'almost-pumper' population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders."</p><p>Pivot is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group, which the Company calls the "almost-pumpers," represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.</p><p>Full commercial launch is expected to roll out in phases, initially targeting select high-volume endocrinology practices and expanding across multiple metropolitan markets by late 2026.</p><p>For more information on the Pivot system, visit the dedicated site: PivotPump.com and the YouTube Pivot Insulin Delivery System channel searchable @ModularMedical.</p><p><strong>Forward-Looking Statements</strong></p><p>This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to convert patients to use its Pivot pump product, whether the Company will have initial users by June 30, 2026, successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, and general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.</p><p><strong>About Modular Medical</strong></p><p>Modular Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/MODD">MODD</a>) is a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."</p><p>Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at <a rel="nofollow" href="https://protect.checkpoint.com/v2/r01/___https:/pr.report/NyQvWeDS___.YXAzOm1vZHVsYXItbWVkaWNhbDpjOm86MmQwYWQ5YTU1YjMyNTE4ZmIzOWJiMTNlYTlmOTkwYzU6NzozNGI4OjI2MTFkNzY0OTRlY2Y0ODgyN2FkZDQ1MzhlZGU1YTcxYjMzZGEwNzVlMDkxZjYxZTExNzFiNjY0N2M2ZmQyMzE6cDpUOk4">https://modular-medical.com</a>.</p><p>Pivot is a trademark of Modular Medical in the United States. All other trademarks mentioned herein are the property of their respective owners.</p><p><strong>Company Contact:</strong><br/>Jeb Besser<br/>Chief Executive Officer<br/>Modular Medical, Inc.<br/>+1 (617) 399-1741<br/><a rel="nofollow" href="mailto:IR@modular-medical.com">IR@modular-medical.com</a></p><p><strong>Investor Relations Contact:</strong><br/>Valter Pinto, Managing Director<br/>KCSA Strategic Communications<br/><a rel="nofollow" href="mailto:ModularMedical@KSCA.com">ModularMedical@KSCA.com</a></p><p><strong>SOURCE: </strong>Modular Medical, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-announces-commercial-availability-of-pivot-tubeless-i-1180351'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1180351" width="0" height="0"/>

Pivot tubeless insulin patch pump is now commercially available in the U.S., signaling Modular Medical's shift to a revenue-generating stage after FDA clearance in April. First shipments have begun, with a phased national rollout planned for late 2026, targeting the large 'almost-pumper' segment, a multi-billion-dollar opportunity that could sustain MODD's near-term growth trajectory.

Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump Ahead of Commercial Expansion

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News